Celldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Now Rated “Moderate Buy” by Wall Street Analysts

by · The Markets Daily

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) have received an average recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $63.08.

A number of equities research analysts recently commented on the stock. Wall Street Zen raised shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. Wells Fargo & Company raised their target price on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Barclays lifted their price target on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $64.00 price target on shares of Celldex Therapeutics in a research report on Friday, October 2nd. Finally, Leerink Partners upped their price target on Celldex Therapeutics from $70.00 to $88.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 23rd.

Read Our Latest Stock Report on CLDX

Celldex Therapeutics Stock Performance

Shares of Celldex Therapeutics stock opened at $29.87 on Tuesday. The company has a market capitalization of $2.35 billion, a PE ratio of -6.95 and a beta of 1.04. The company has a 50-day simple moving average of $32.93 and a two-hundred day simple moving average of $32.68. Celldex Therapeutics has a one year low of $22.10 and a one year high of $45.14.

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.96) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.06. The firm had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.72 million. On average, equities analysts predict that Celldex Therapeutics will post -4.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CLDX. Diversified Trust Co boosted its holdings in Celldex Therapeutics by 2.9% in the third quarter. Diversified Trust Co now owns 32,239 shares of the biopharmaceutical company’s stock worth $1,045,000 after acquiring an additional 909 shares in the last quarter. Fisher Asset Management LLC increased its holdings in shares of Celldex Therapeutics by 26.5% during the third quarter. Fisher Asset Management LLC now owns 1,246,855 shares of the biopharmaceutical company’s stock valued at $40,411,000 after acquiring an additional 261,178 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Celldex Therapeutics by 11.0% during the third quarter. Russell Investments Group Ltd. now owns 111,489 shares of the biopharmaceutical company’s stock valued at $3,613,000 after acquiring an additional 11,037 shares in the last quarter. Three Bridge Wealth Advisors LLC acquired a new position in shares of Celldex Therapeutics during the third quarter valued at about $40,000. Finally, Candriam S.C.A. increased its holdings in shares of Celldex Therapeutics by 7.8% during the third quarter. Candriam S.C.A. now owns 518,476 shares of the biopharmaceutical company’s stock valued at $16,865,000 after acquiring an additional 37,351 shares in the last quarter.

About Celldex Therapeutics

(Get Free Report)

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapeutics for diseases with significant unmet medical needs. The company uses antibody-based technologies to develop treatments intended to modulate the immune system and address inflammatory, autoimmune and other serious conditions.

Celldex’s lead investigational product is barzolvolimab, an antibody designed to selectively block the KIT receptor and reduce mast-cell activity.

Featured Stories